Calcium Channel Blockers

Cardiovascular collapse in association with marked hyperkalemia reported; intravenous dantrolene not recommended with calcium channel blockers during malignant hyperthermia crisis.

Cardiovascular collapse and marked hyperkalemia reported. IV dantrolene sodium should not be used with calcium channel blockers during malignant hyperthermia crisis management.

Additive effect when given with atenolol; may cause enhanced negative inotropic and chronotropic effects.

Additive effects may occur when given with atenolol and chlorthalidone, potentially causing excessive cardiovascular depression.

Avoid concomitant use; calcium chloride may reduce response to calcium channel blockers. Monitor blood pressure closely if use unavoidable.

Calcium chloride may reduce response to calcium channel blockers. Avoid concomitant use; monitor blood pressure closely if unavoidable.

Additive effects such as bradycardia and AV block may occur. Sinus bradycardia resulting in hospitalization and pacemaker insertion reported with diltiazem or verapamil.

Monitor heart rate; sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported with some calcium channel blockers.

Monitor heart rate; calcium channel blockers affect sinus node function and AV nodal conduction. Sinus bradycardia with hospitalization and pacemaker insertion reported.

Non-dihydropyridine calcium channel blockers cause bradycardia and should be avoided with crizotinib, which can also cause bradycardia.

Potential pharmacodynamic interaction; certain calcium channel blockers may prolong QT interval.

Marked symptomatic orthostatic hypotension reported when combined with organic nitrates. Dose adjustments of either agent may be necessary.

Concurrent use may increase neurotoxicity risk (ataxia, tremors, nausea, vomiting, diarrhea, tinnitus). Close monitoring required.

Concomitant administration produces additive reduction in myocardial contractility due to negative chronotropic and inotropic effects.

Marked symptomatic orthostatic hypotension reported when combined with organic nitrates. Dose adjustments of either class may be necessary.

Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly.

Additive effects on atrioventricular conduction and ventricular function. Monitor for bradycardia and hypotension.

Calcium channel-blocking drugs produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

Given with adenosine without apparent adverse interactions, but adenosine should be used with caution due to potential additive depressant effects on SA and AV nodes.

May produce hyperglycemia and lead to loss of glycemic control.

Administration of calcium may reduce the response to calcium channel blockers.

Produce hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.

Although may be useful in combination with digoxin, additive effects on AV node conduction can result in advanced or complete heart block.

May potentiate dronedarone's effects on conduction. Initiate with low dose and increase after ECG verification of tolerability.

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

Concomitant use with ELLENCE may cause heart failure. Close monitoring of cardiac function required throughout treatment.

May produce hyperglycemia and lead to loss of glycemic control; close monitoring recommended.

Calcium channel blocking drugs may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Calcium channel blockers may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Calcium channel blockers may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.

Calcium channel blocking drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.

Imatinib increases plasma concentration of dihydropyridine calcium channel blockers; use caution with drugs having narrow therapeutic window.

Imatinib increases plasma concentration of CYP3A4 metabolized dihydropyridine calcium channel blockers. Use caution with drugs that have narrow therapeutic window.

Lacosamide should be used with caution with sodium channel blockers due to risk of AV block, bradycardia, or ventricular tachyarrhythmia. ECG monitoring recommended.

Use with caution due to risk of AV block, bradycardia, or ventricular tachyarrhythmia. ECG monitoring before initiation and after titration is recommended.

Calcium channel blockers may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

Concomitant use may produce additive reduction in myocardial contractility due to negative chronotropic and inotropic effects.

Antagonistic effects decrease phenylephrine blood pressure effect.

CYP3A inhibitors; concomitant use in patients with widespread and/or erythrodermic disease should be done with caution due to potential for increased pimecrolimus levels.

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.

CYP3A4 inhibitors; concomitant administration in patients with widespread and/or erythrodermic disease should be done with caution.

CYP3A4 inhibitors; concomitant use in patients with widespread and/or erythrodermic disease should be done with caution due to potential increased tacrolimus absorption.

Calcium channel blockers may cause additive bradycardic effect with thalidomide and should be used with caution.

Could enhance the rate of VISUDYNE uptake by the vascular endothelium, potentially increasing photodynamic effects.